Top

Published in:

Open Access 01-12-2015 | Case report

En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review

Authors: Tong Meng, Wang Zhou, Bo Li, Huabin Yin, Zhenxi Li, Lei Zhou, Jinhai Kong, Wangjun Yan, Xinghai Yang, Tielong Liu, Dianwen Song, Jianru Xiao

Published in: World Journal of Surgical Oncology | Issue 1/2015

Abstract

Background

Tumor-induced osteomalacia (TIO) is a rare disorder, which is commonly found in craniofacial locations and in the extremities. To the best of our knowledge, only 16 cases have been described in the spine, and this is the first report to describe a case of patient with TIO in the thoracic spine combined with a mesenchymal hamartoma which had confused the therapeutic strategies to date.

Case description

We report the case of a 60-year-old patient with hypophosphatemia and presented with limb weakness. Treating with phosphate did not correct the hypophosphatemia and an ¹¹¹In pentetreotide scintigraphy (octreotide scan) revealed an increased uptake at the right forearm. The tumor was resected totally, and the histopathology revealed a mesenchymal hamartoma, but we noticed that hypophosphatemia was not corrected after the tumor resection. Then a whole-body magnetic resonance imaging (WB-MRI) was performed and the results revealed tumorous tissues at the right T1 vertebral pedicle. The tumor was removed with an en bloc method, and the pathology showed phosphaturic mesenchymal tumor. Follow-up at 1 year after surgery revealed no recurrence, and the serum phosphorus level of the patient was normal.

Conclusions

Tumor-induced osteomalacia is exceedingly rare with only 16 cases in spine published in the literature. It is difficult to find and leads to years of suffering debilitating complications. In this regard, the WB-MRI is a better method to locate the real tumor. Treating with phosphate can only relieve symptoms, and a complete surgical removal remains the gold standard treatment.

de Beur SM J. Tumor-induced osteomalacia. JAMA. 2005;294:1260–7.CrossRef

Econs MJ, Drezner MK. Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med. 1994;330:1679–81.CrossRefPubMed

Carpenter TO. Oncogenic osteomalacia - a complex dance of factors. N Engl J Med. 2003;348:1705–8.CrossRefPubMed

Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442–54.CrossRefPubMed

Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.CrossRefPubMed

Mc CR. Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16:33–46.

Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967–75.CrossRefPubMed

Boriani S, Campanacci M. Osteoblastoma associated with osteomalacia (presentation of a case and review of the literature). Ital J Orthop Traumatol. 1978;4:379–82.PubMed

Stone MD, Quincey C, Hosking DJ. A neuroendocrine cause of oncogenic osteomalacia. J Pathol. 1992;167:181–5.CrossRefPubMed

10.

Yu GH, Katz RL, Raymond AK, Gagel RF, Allison A, McCutcheon I. Oncogenous osteomalacia: fine needle aspiration of a neoplasm with a unique endocrinologic presentation. Acta Cytol. 1995;39:831–2.PubMed

11.

Terek RM. Nielsen GP:Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2001. A 14-year-old with abnormal bones and a sacral mass. N Engl J Med. 2001;345:903–8.CrossRef

12.

Chua SC, O’Connor SR, Wong WL, Ganatra RH. Case report: solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br J Radiol. 2008;81:e110–114.CrossRefPubMed

13.

Sciubba DM, Petteys RJ, Shakur SF, Gokaslan ZL, McCarthy EF, Collins MT, et al. En bloc spondylectomy for treatment of tumor-induced osteomalacia. J Neurosurg Spine. 2009;11:600–4.CrossRefPubMed

14.

Pirola E, Vergani F, Casiraghi P, Leone EB, Guerra P, Sganzerla EP. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the thoracic spine. J Neurosurg Spine. 2009;10:329–33.CrossRefPubMed

15.

Mavrogenis AF, Sakellariou VI, Soultanis K, Mahera H, Korres DS, Papagelopoulos PJ. A nonphosphaturic mesenchymal tumor mixed connective tissue variant of the sacrum. Orthopedics. 2010;33:851.PubMed

16.

Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC, et al. A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathol. 2010;20:499–502.CrossRefPubMed

17.

Akhter M, Sugrue PA, Bains R, Khavkin YA. Oncogenic osteomalacia of the cervical spine: a rare case of curative resection and reconstruction. J Neurosurg Spine. 2011;14:453–6.CrossRefPubMed

18.

Gandhi GY, Shah AA, Wu KJ, Gupta V, Shoraka AR. Tumor-induced osteomalacia caused by primary fibroblast growth factor 23 secreting neoplasm in axial skeleton: a case report. Case Rep Endocrinol. 2012;2012:185454.PubMedCentralPubMed

19.

Nakamura T, Aizawa T, Hoshikawa T, Ozawa H, Ito N, Fukumoto S, et al: Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. J Orthop Sci 2014 DOI: 10.1007/s00776-014-0540-4

20.

Rodgers SE, Perrier ND. Parathyroid carcinoma. Curr Opin Oncol. 2006;18:16–22.CrossRefPubMed

21.

Vollbrecht JE, Rao DS. Images in clinical medicine. Tumor-induced osteomalacia N Engl J Med. 2008;358:1282.CrossRef

22.

Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92:2374–7.CrossRefPubMed

23.

Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45:814–6.CrossRefPubMed

24.

Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332–7.CrossRefPubMed

25.

Cukierman T, Gatt ME, Hiller N, Chajek-Shaul T. Clinical problem-solving. A fractured diagnosis. N Engl J Med. 2005;353:509–14.CrossRefPubMed

26.

Palot Manzil FF, Bhambhvani PG, O’Malley JP. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy. J Nucl Med Technol. 2013;41:299–301.CrossRefPubMed

27.

Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130–1.CrossRefPubMed

28.

Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–62.CrossRefPubMed

29.

Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med. 2007;32:300–1.CrossRefPubMed

30.

Nakanishi K, Sakai M, Tanaka H, Tsuboi H, Hashimoto J, Hashimoto N, et al. Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia. Magn Reson Med Sci. 2013;12:47–52.CrossRefPubMed

31.

Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone. 1999;25:375–7.CrossRefPubMed

32.

Nelson AE, Mason RS, Robinson BG, Hogan JJ, Martin EA, Ahlstrom H, et al. Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. Eur J Endocrinol. 2001;145:469–76.CrossRefPubMed

33.

Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997;12:1502–11.CrossRefPubMed

34.

Mankin HJ. Rickets, osteomalacia, and renal osteodystrophy. Part II J Bone Joint Surg Am. 1974;56:352–86.

35.

Meng T, Yin H, Li Z, Li B, Zhou W, Wang J, et al. Therapeutic strategy and outcome of spine tumors in pregnancy: a report of 21 cases and literature review. Spine (Phila Pa 1976). 2015;40:E146–153.CrossRef

36.

Meng T, Yin H, Li B, Li Z, Xu W, Zhou W, et al. Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center. Neuro Oncol. 2015;17:725–32.CrossRefPubMed

37.

Dissanayake AM, Wilson JL, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging. Intern Med J. 2003;33:615–6.CrossRefPubMed

38.

Puthenveetil PJ, Hattab EM, Peacock M, Horn EM. Thoracic phosphaturic mesenchymal tumors causing oncogenic osteomalacia. J Clin Neurosci. 2013;20:1057–61.CrossRefPubMed

Title: En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review
Authors: Tong Meng
Wang Zhou
Bo Li
Huabin Yin
Zhenxi Li
Lei Zhou
Jinhai Kong
Wangjun Yan
Xinghai Yang
Tielong Liu
Dianwen Song
Jianru Xiao
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-015-0589-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review

Abstract

Background

Case description

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case description

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Long-term survival with complete remission after hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer: a case report

The prognostic significance of a postoperative systemic inflammatory response in patients with colorectal cancer

Adult classical glioblastoma with a BRAF V600E mutation

Mucinous adenocarcinoma emerging in sigmoid colon neovagina 40 years after its creation: a case report

The iatrogenic injury of double vena cava due to misdiagnosis during the radical nephroureterectomy and cystectomy

Effects of sex hormones on survival of peritoneal mesothelioma